Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSTAT vs ADDERALL 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
FDA-approved for attention deficit hyperactivity disorder (ADHD) and narcolepsy. Off-label uses include treatment-resistant depression, obesity, and cognitive enhancement in certain conditions.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Primarily metabolized by hepatic CYP2D6 enzymes to inactive metabolites; also undergoes deamination and oxidation.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
15-40% bound to plasma proteins, primarily albumin.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
Approximately 3-4 L/kg, suggesting extensive tissue distribution.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Oral: approximately 60-70% due to first-pass metabolism; extended-release formulations have comparable bioavailability.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
No specific guideline; use with caution and monitor for adverse effects in severe renal impairment (e GFR <30 m L/min/1.73m²).
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
No specific guideline; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
For ADHD: Children 6 years and older, start with 5 mg once or twice daily, increase by 5 mg weekly as tolerated; maximum 40 mg/day. Weight-based: 0.3-0.6 mg/kg/day.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
Start at lower doses, e.g., 2.5 mg once or twice daily, due to increased sensitivity and risk of side effects; monitor blood pressure and cardiac status.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
High potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Blood pressure and heart rate increase; monitor for hypertension and tachycardia.,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression.,Seizures: may lower seizure threshold.,Peripheral vasculopathy including Raynaud's phenomenon.,Serotonin syndrome risk if used with serotonergic drugs.,Growth suppression in children; monitor growth during long-term use.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Hypersensitivity to amphetamines or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to hypertensive crisis.,Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Avoid acidic foods and juices (e.g., orange juice, grapefruit juice) within 1 hour of administration as they can reduce absorption. High-fat meals may delay absorption. Avoid alcohol and caffeine as they can exacerbate side effects.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth restriction, increased neonatal heart rate, and neonatal withdrawal syndrome. Avoid use during pregnancy unless potential benefit justifies risk.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
Amphetamines are excreted in human milk. M/P ratio not established. Breastfeeding not recommended due to potential adverse effects in infants including irritability, poor feeding, and growth suppression.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Pregnancy may increase clearance of amphetamines; dose adjustments may be necessary. Use the lowest effective dose. Clinical monitoring recommended.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
Dextrostat (dextroamphetamine) is a central nervous system stimulant used for ADHD and narcolepsy. Monitor for hypertension, tachycardia, and psychiatric adverse effects. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or severe anxiety. Taper to discontinue to avoid withdrawal. Use with caution in patients with a history of substance abuse. May reduce seizure threshold.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,Do not crush or chew extended-release capsules.,Avoid alcohol and over-the-counter cold remedies containing decongestants.,Store in a secure place; misuse can cause serious health problems.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSTAT vs ADDERALL 10, answered by our medical review team.
DEXTROSTAT is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.. ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSTAT and ADDERALL 10 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSTAT is: 5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.. The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSTAT and ADDERALL 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSTAT is classified as Category C. First trimester: Limited data, but amphetamine use is associated with increased risk of premature delivery and low birth weight. Second and third trimesters: Risk of fetal growth r. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.